Bipolar, schizophrenia and other psychoses: target organ damage

This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

Last reviewed: August 2019

Next review: March 2027

This indicator will be reviewed using the assessment criteria in Appendix B of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

This indicator was previously published as NM21.

How to use NICE indicators and how we develop them

Indicators can be used in a number of different settings to support high quality care. These include:

• identifying where improvements are needed
• setting priorities for quality improvement and support
• creating local performance dashboards
• benchmarking performance against national data
• supporting local quality improvement schemes
• showing progress that local health systems are making on outcomes.

Find out how to use indicators and how we develop them.